2024
1299P First-line immunotherapy versus BRAF and MEK inhibitors for patients with BRAF V600E mutant metastatic non-small cell lung cancer
Di Federico A, Chen M, Pagliaro A, Ogliari F, Stockhammer P, Aldea M, Grant M, De Giglio A, Alessi J, Pecci F, Gelsomino F, Negrao M, Ferrara R, Awad M, Riely G, Ardizzoni A, Planchard D, Offin M, Johnson B, Ricciuti B. 1299P First-line immunotherapy versus BRAF and MEK inhibitors for patients with BRAF V600E mutant metastatic non-small cell lung cancer. Annals Of Oncology 2024, 35: s826-s827. DOI: 10.1016/j.annonc.2024.08.1356.Peer-Reviewed Original Research
2023
Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations
Grant M, Aredo J, Starrett J, Stockhammer P, van Rosenburgh I, Wurtz A, Piper-Valillo A, Piotrowska Z, Falcon C, Yu H, Aggarwal C, Scholes D, Patil T, Nguyen C, Phadke M, Li F, Neal J, Lemmon M, Walther Z, Politi K, Goldberg S. Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations. Clinical Cancer Research 2023, 29: of1-of8. PMID: 36913537, PMCID: PMC10493186, DOI: 10.1158/1078-0432.ccr-22-3497.Peer-Reviewed Original ResearchConceptsProgression-free survivalNon-small cell lung cancerInferior progression-free survivalMulticenter retrospective cohortEfficacy of osimertinibMulti-institutional cohortCell lung cancerExon 19 deletion mutationUncommon EGFRRetrospective cohortClinical outcomesClinical efficacyLung cancerOsimertinib efficacyEGFR mutationsPreclinical modelsEx19delPatientsAACR Genie databaseLater linesOsimertinibMutant cohortFirst lineCohortEfficacy
2019
1849P Pleural effusion TGF-beta is highly diagnostic and prognostic in malignant pleural mesothelioma
Stockhammer P, Ploenes T, Schuler M, Langer S, Aigner C, Hegedus B. 1849P Pleural effusion TGF-beta is highly diagnostic and prognostic in malignant pleural mesothelioma. Annals Of Oncology 2019, 30: v750-v751. DOI: 10.1093/annonc/mdz266.008.Peer-Reviewed Original ResearchMalignant pleural mesotheliomaNon-malignant pleural diseaseTGF-β levelsMPM patientsPleural mesotheliomaNon-epithelioid malignant pleural mesotheliomaMultivariate Cox regression modelWorse overall survivalCox regression modelFuture clinical trialsPleural effusion samplesAdvanced diseaseMultimodality treatmentOverall survivalDismal prognosisEpithelioid tumorsPleural effusionPleural diseaseAggressive malignancyClinical trialsPrognostic biomarkerPatientsReliable biomarkersEffusion samplesSignificant negative correlationP1.14-43 A Novel Patient Derived Synchronous Cell Pair with Different Mutations in an ALK-Rearranged Lung Adenocarcinoma Underlines Tumor Heterogeneity
Stockhammer P, Ho C, Bankfalvi A, Plönes T, Hegedus L, Schuler M, Aigner C, Schramm A, Hegedus B. P1.14-43 A Novel Patient Derived Synchronous Cell Pair with Different Mutations in an ALK-Rearranged Lung Adenocarcinoma Underlines Tumor Heterogeneity. Journal Of Thoracic Oncology 2019, 14: s571-s572. DOI: 10.1016/j.jtho.2019.08.1194.Peer-Reviewed Original Research
2017
Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma
Klikovits T, Stockhammer P, Laszlo V, Dong Y, Hoda MA, Ghanim B, Opitz I, Frauenfelder T, Nguyen-Kim TDL, Weder W, Berger W, Grusch M, Aigner C, Klepetko W, Dome B, Renyi-Vamos F, Oehler R, Hegedus B. Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma. Scientific Reports 2017, 7: 16456. PMID: 29184132, PMCID: PMC5705645, DOI: 10.1038/s41598-017-16551-7.Peer-Reviewed Original ResearchConceptsMalignant pleural mesotheliomaNon-malignant pleural diseasePlasma C4d levelsC4d levelsHealthy volunteersInduction chemotherapyMPM patientsPleural mesotheliomaTumor volumeMultivariate Cox regression modelEctopic lymphoid structuresBetter overall survivalCox regression modelHigher tumor volumeNew prognostic biomarkerPlasma C4dOverall survivalProgressive diseaseLymphoid structuresPleural diseaseC4d immunohistochemistryPrognostic biomarkerTumor stromaPatientsChemotherapeutic responseOA02.03 Circulating Fibroblast Growth Factor 18 is Elevated in Malignant Pleural Mesothelioma Patients - A Multi-Institutional Study
Dong Y, Zhang H, Schelch K, Klikovits T, Stockhammer P, Jakopovic M, Samarzija M, Brcic L, Reid G, Kirschner M, Kao S, Opitz I, Weder W, Frauenfelder T, Nguyen-Kim T, Klepetko W, Van Zandwijk N, Hegedus B, Berger W, Dome B, Laszlo V, Grusch M, Hoda M. OA02.03 Circulating Fibroblast Growth Factor 18 is Elevated in Malignant Pleural Mesothelioma Patients - A Multi-Institutional Study. Journal Of Thoracic Oncology 2017, 12: s247-s248. DOI: 10.1016/j.jtho.2016.11.234.Peer-Reviewed Original Research